May 24, 2018 / 11:12 AM / 5 months ago

FDA declines to approve Recro Pharma's non-opioid pain shot

The U.S. Food and Drug Administration on Thursday declined to approve Recro Pharma's IV meloxicam noting the pain-relieving effect of the drug did not meet its expectations.

The drug is a non-opioid injection to treat moderate-to-severe pain.

Unlike the drug's oral version, which has been on the market for several years, Recro's intravenous formulation is long-acting for treating acute pain, particularly in patients who have undergone surgery. (Reporting by Sharnya G and Tamara Mathias; Editing by Shailesh Kuber)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below